DHTs as Endpoints in Device Investigations: Investigational Device vs Measurement Tool
FDA DHT clinical investigation guide: investigational device vs remote measurement tool under 21 CFR 812, fit-for-purpose V&V, and August 2026 DDM status.
In modern medical device clinical investigations, sponsors increasingly deploy digital health technologies (DHTs)—such as continuous biometric wearables, mobile sensor patches, connected spirometers, and smartphone-based gait trackers—to capture clinical outcome data outside traditional hospital visits.
However, clinical trial sponsors, regulatory affairs (RA) professionals, and biostatisticians encounter a fundamental regulatory fork: is the deployed DHT itself an investigational device requiring full Investigational Device Exemption (IDE under 21 CFR Part 812) oversight, or is it merely an endpoint measurement tool subject to fit-for-purpose verification and validation? Furthermore, device sponsors must navigate the Food and Drug Administration (FDA) December 2023 final guidance on remote data acquisition, understand the precise legal boundaries of investigation-only design control discretion, distinguish between official guidance and the multi-center August 2026 discussion paper on digitally derived measures (DDMs), and avoid the common pitfall of assuming that an existing 510(k) clearance or Medical Device Development Tool (MDDT) qualification eliminates the need for protocol-specific clinical validation.
The Core Direct Answer: In a medical device clinical study, a Digital Health Technology (DHT) occupies one of two distinct regulatory roles:
- The Investigational Article: If the clinical investigation is designed to evaluate the safety, effectiveness, diagnostic performance, or marketing claims of the DHT itself, the DHT is an investigational device governed by 21 CFR Part 812 (Significant Risk / Non-Significant Risk IDE requirements) in the United States and MDR Articles 62–82 under ISO 14155:2026 in the European Union.
- The Remote Measurement Tool: If the DHT is used solely as a data-capture instrument to measure the clinical performance or primary/secondary endpoints of another investigational medical device (such as an orthopedic implant, cardiovascular stent, or neuromodulator), the DHT is evaluated under FDA's December 2023 final guidance, "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations" (Docket No. FDA-2021-D-1128, FR 2023-28262).
Under the December 2023 final guidance, FDA requires fit-for-purpose verification and validation (V&V) for any DHT used for remote data acquisition, regardless of whether the DHT meets the definition of a medical device under Section 201(h) of the FD&C Act.
Furthermore, FDA exercises investigation-only design control discretion: if a DHT that meets the statutory definition of a medical device is used solely for remote data collection in a clinical investigation and the recommended V&V is completed to establish fit-for-purpose, FDA does not intend to otherwise assess sponsors' compliance with design control requirements (see 21 CFR 820.30 in the guidance footnotes). This discretion does not apply if the DHT is intended for commercial marketing outside the investigation. It is also not itself a 510(k), De Novo, PMA, or CE-mark.
Sponsors must also recognize that the August 2026 document "Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations" (issued jointly by CBER, CDER, CDRH, and OCE; FDA Voices content current as of August 20, 2026) is explicitly a discussion paper, not formal FDA guidance. Finally, citing a cleared 510(k) on a commercial wearable or an MDDT qualification (such as the Apple AFib History Feature) does not waive the sponsor's duty to demonstrate that the DHT is fit-for-purpose in the specific trial population, wear environment, and statistical estimand framework.
Status Summary: DHT as Investigational Device vs. Endpoint Measurement Tool
The following matrix contrasts the statutory authority, regulatory burdens, and operational requirements across the two distinct DHT trial roles:
| Dimension | DHT as Investigational Device (Primary Subject) | DHT as Remote Measurement Tool (Data Capture Instrument) |
|---|---|---|
| Regulatory Authority | 21 CFR Part 812 (IDE); FD&C Act Section 520(g); EU MDR Articles 62–82. | FDA December 2023 Final Guidance (Docket FDA-2021-D-1128); 21 CFR Part 312 / 812 study protocols. |
| Primary Clinical Objective | Generate clinical evidence to clear or approve the DHT itself (e.g., novel wearable diagnostic algorithm). | Measure clinical endpoints (e.g., continuous activity, sleep apnea index) for a separate medical product. |
| IDE Determination Required | Yes: Formal Significant Risk (SR) vs. Non-Significant Risk (NSR) determination by IRB / FDA. | No: IDE attaches to the primary investigational article; DHT is reviewed as a protocol measurement tool. |
| Design Controls (21 CFR § 820.30) | Mandatory: Full design history file, design inputs, verification, validation, and design transfer. | Investigation-only discretion: FDA does not intend to otherwise assess sponsors' compliance with design control requirements for a device-DHT used solely for remote data collection when recommended fit-for-purpose V&V is done. |
| Verification & Validation Duty | Full design verification and clinical validation to support commercial marketing authorization. | Fit-for-Purpose V&V: Sensor verification, clinical validation in trial cohort, usability, data security. |
| August 2026 DDM Document Status | Contextual scientific framework (Discussion paper; not binding guidance). | Contextual framework for defining meaningful aspects of health (MAH) and concepts of interest (COI). |
| Pre-Existing 510(k) Clearance | If cleared for a different intended use, off-label investigation may still trigger Part 812 IDE rules. | Helpful for baseline hardware safety/EMC, but does not replace protocol-specific clinical V&V. |
| Government Filing Fees | Standard MDUFA fees if IDE / marketing submission required ($0 for initial IDE application). | $0 FDA User Fee (No federal fee to deploy a DHT measurement tool in a clinical investigation). |
The Core Fork: Is Your DHT the Investigational Article or the Measurement Tool?
Before authoring a Clinical Investigational Plan (CIP) under ISO 14155 or an FDA IDE submission under 21 CFR Part 812, the sponsor must formally classify the role of the digital technology.
| Is the trial designed to support marketing authorization or diagnostic claims for the DHT itself? | Result |
|---|---|
| Yes | The DHT is the investigational article under 21 CFR Part 812 / MDR Articles 62–82. Determine SR vs NSR; an SR study needs FDA IDE approval before start. Full design controls apply. |
| No — the DHT only captures endpoints for another investigational product | Remote measurement tool under the December 2023 final guidance. Fit-for-purpose V&V is required. Investigation-only design-control discretion may apply if the DHT is used solely for remote data collection and is not marketed from the trial. |
Scenario A: The DHT as the Investigational Device
Consider a digital health company developing an AI-driven smart ring that detects early signs of congestive heart failure decompensation. The clinical trial is designed specifically to gather clinical sensitivity, specificity, and safety data to submit a De Novo or 510(k) application for the ring.
- The ring is the investigational article.
- The sponsor must assess whether the ring poses Significant Risk (SR) or Non-Significant Risk (NSR) under 21 CFR Part 812 IDE regulations.
- Full design controls under 21 CFR § 820.30 / FDA QMSR apply, including software lifecycle documentation under IEC 62304.
Scenario B: The DHT as the Remote Measurement Tool
Consider an orthopedic manufacturer conducting a pivotal IDE clinical trial for a novel total knee replacement system. To capture objective post-operative physical mobility, the protocol provides all subjects with an off-the-shelf commercial smartwatch to record continuous daily step counts and active minutes over a 12-month follow-up.
- The knee implant is the investigational article.
- The smartwatch is a remote measurement tool providing secondary clinical endpoint data.
- The smartwatch does not become an investigational device under 21 CFR 812.
- The sponsor must provide documentation in the IDE protocol demonstrating that the smartwatch accurately, reliably, and securely measures physical activity in post-arthroplasty patients under the December 2023 guidance.
What Does Fit-for-Purpose Verification and Validation Actually Require?
Under the December 2023 final guidance, FDA defines fit-for-purpose as a conclusion that the level of validation associated with a DHT is sufficient to support its use and the interpretability of data in the clinical investigation.
Sponsors must assemble a distinct V&V dossier within their clinical trial master file, evaluating three progressive tiers of evidence:
| Tier | What it shows |
|---|---|
| Technical verification (analytical performance) | Sensor precision, accuracy, resolution, repeatability; bench benchmarking; environmental robustness. |
| Clinical validation (clinical performance) | The DHT measures the intended event or characteristic in the trial population, compared with an established reference where one exists. |
| Usability and operational integrity | Interface, adherence, battery, buffering during connectivity loss, and secure transfer into a Part 11-compliant EDC. |
1. Verification (Analytical Validation)
Verification evaluates the fundamental sensor and software algorithm to confirm it accurately measures the physical parameter it claims to measure. For example, for an optical photoplethysmography (PPG) sensor, verification involves bench testing against calibrated pulse generators across diverse simulated skin pigmentation levels, perfusion indexes, and ambient light conditions.
2. Validation (Clinical Validation)
Clinical validation evaluates whether the digital measurement accurately identifies, measures, or predicts the clinical phenomenon in human subjects representing the trial cohort. If a wearable accelerometer algorithm was originally developed on healthy, young marathon runners, it cannot be assumed to be clinically valid for measuring step counts in elderly patients with severe osteoarthritic gait impairments without direct clinical validation in that specific cohort.
When evaluating specialized endpoint science, reviewing expert methodologies on fit-for-purpose verification and validation for DHT-derived endpoints provides vital clinical insight into developing validation protocols, establishing reference gold standards, and structuring endpoint dossiers for regulatory review.
When Does Investigation-Only Design-Control Discretion Apply, and When Does It Not?
A cornerstone of the December 2023 final guidance is FDA's statement on design-control assessment for DHTs used only as remote data-collection tools. The PDF states that where sponsors conduct the recommended verification and validation so a DHT used only in clinical investigations for remote data collection is fit-for-purpose, FDA does not intend to otherwise assess sponsors' compliance with design control requirements (footnotes point to 21 CFR 820.30).
| Discretion applies when | Discretion does not apply when |
|---|---|
| The DHT is used solely for remote data acquisition in the investigation, recommended V&V is done, and the DHT is not being commercialized from that use. | The DHT is intended for commercial marketing outside the investigation; it is itself the investigational article seeking 510(k)/De Novo/PMA; or it is not limited to remote data collection (for example, it delivers real-time alerts that change acute therapy). Discretion is not a marketing authorization. |
Critical Boundaries of Enforcement Discretion
- Not a Marketing Authorization: This policy is an enforcement posture for clinical trials; it does not grant a 510(k), De Novo, PMA, or CE-mark. The sponsor cannot commercialize or sell the measurement DHT to hospitals based on this discretion.
- Real-Time Clinical Decision Support Tripwire: If the DHT is configured to deliver real-time diagnostic alerts to clinicians that alter patient medication or intervention during the trial (e.g., an automated arrhythmia alarm prompting emergency antiarrhythmic drug dosing), it crosses from a passive measurement tool into an active clinical management device, voiding investigation-only discretion.
Is the August 2026 Digitally Derived Measures Paper Guidance?
On August 20, 2026, FDA Voices published commentary accompanying a collaborative cross-center document titled Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations (CBER, CDER, CDRH, and the Oncology Center of Excellence). The paper PDF is dated August 2026; the Voices page is content-current as of August 20, 2026.
| Question | Answer |
|---|---|
| Is this FDA guidance? | No. It is a discussion paper / white paper drawing on existing guidances. It does not create enforceable new duties and does not replace the December 2023 DHT guidance. |
| What taxonomy does it use? | Digitally derived measures (DDMs) as COAs, biomarkers, or multicomponent endpoints. Start from a Meaningful Aspect of Health (MAH), then a Concept of Interest (COI)—not from whichever sensor is already in the cabinet. |
Key Principles from the 2026 Discussion Paper
Device sponsors referencing the August 2026 paper must observe several foundational concepts:
- Meaningful Aspect of Health (MAH) First: Sponsors should not begin endpoint development by selecting a commercial sensor and searching for data it can collect. Instead, endpoint design must begin by identifying what aspect of the patient's disease or recovery matters to the patient (e.g., ability to sleep without pain, physical endurance).
- Concept of Interest (COI) Mapping: Define the specific measurable characteristic that reflects the MAH (e.g., continuous sleep fragmentation index, active walking bouts >10 minutes).
- Integration with Estimands: In the study's Statistical Analysis Plan (SAP) under ICH E9(R1), the digitally derived measure must be rigorously integrated into the primary or secondary estimand, defining how intercurrent events (e.g., device removal, sensor failure, non-compliance) and missing data will be addressed.
Does an MDDT Qualification or a Wearable 510(k) Replace Protocol-Specific V&V?
A frequent misconception among medical device clinical teams is assuming that selecting a commercial smartwatch that already possesses FDA 510(k) clearance or citing an FDA-qualified Medical Device Development Tool (MDDT) waives the requirement for trial-specific verification and validation.
| Starting point | What it does not finish |
|---|---|
| Commercial 510(k) on a wearable (e.g., OTC pulse or step counting) | Does not prove investigation-specific accuracy or sensitivity to change in the trial cohort. Protocol-specific fit-for-purpose V&V is still required. |
| Qualified MDDT used exactly within its Context of Use (COU) | Reviewers may rely on the qualification for that COU; the sponsor still has to show operational integration. |
| Qualified MDDT used outside its COU (different population, setting, or claim) | Qualification does not apply. Full V&V is required. |
The Role of FDA's MDDT Program
Under the FDA Medical Device Development Tool (MDDT) program authorized under Section 507 of the FD&C Act, FDA qualifies specific tools (clinical outcome assessments, biomarker assays, non-clinical models) for an explicit Context of Use (COU).
- While qualifications such as the Apple Watch Atrial Fibrillation History Feature establish regulatory reliance within their exact qualified population and study design, any deployment outside that COU requires independent verification and validation.
- Similarly, deploying patient-reported outcome (ePRO) tools on digital platforms requires psychometric validation alongside electronic interface validation.
The "DHTs for Drug Development" Wrong-Page Trap
When researching regulatory requirements for digital endpoints, search engines frequently direct sponsors to FDA's webpage titled "Digital Health Technologies (DHTs) for Drug Development".
Device trial sponsors must recognize that this portal is administered by the Center for Drug Evaluation and Research (CDER) under Title 21 of the Code of Federal Regulations governing pharmaceutical Investigational New Drug (IND) applications. While the underlying measurement science aligns, the statutory authority for medical device investigations resides within CDRH under 21 CFR Part 812 and the December 2023 cross-center guidance.
How Should Device Sponsors Treat DHT Endpoints in a Non-Inferiority Design?
When designing a pivotal medical device trial utilizing a non-inferiority design, deploying a continuous DHT endpoint introduces critical statistical and methodological complexities.
| Issue | What the December 2023 guidance requires you to confront |
|---|---|
| Historical NI margin from episodic in-clinic tests (e.g., 6-minute walk at a single visit) | A continuous DHT of a related concept is not automatically the same endpoint. Variance, diurnal pattern, and missingness differ. |
| Using that historical effect size as the NI margin for DHT data | FDA states a non-inferiority analysis using a DHT-derived endpoint may be inappropriate if the effect size of the active comparator was not established using similar DHT measurements. |
| What to do instead | Do not silently substitute. Quantify DHT variance (often in a pilot) and align the margin and estimand with CDRH through a Q-Submission. |
The December 2023 final guidance cautions that a non-inferiority analysis using a DHT-derived endpoint may be inappropriate if the effect size of the active comparator was not established using similar DHT measurements. Continuous remote monitoring also captures day-to-day lifestyle variability, weekend versus weekday activity differences, and transient non-wear intervals, so the variance structure differs from standardized in-clinic assessments.
Sponsors must conduct prospective pilot studies to quantify endpoint variance or engage CDRH early through a Pre-Submission (Q-Submission) to align on non-inferiority margin definitions.
What Does DHT Endpoint V&V Cost: Sponsor Testing versus MDUFA versus No DHT User Fee?
Budgeting digital health endpoint deployment requires distinguishing between sponsor-driven analytical costs and official regulatory fees.
| Category | Basis | Amount |
|---|---|---|
| FDA user fee to use a DHT only as a measurement tool in an IDE | Official: no separate DHT endpoint user fee | $0 |
| FDA user fee for an MDDT qualification submission | Official: MDDT qualification is not an MDUFA application | $0 |
| MDUFA fees | Official schedule applies if the DHT (or the primary device) seeks commercial marketing authorization | See the current FY 2027 MDUFA schedule |
| Bench verification (precision, accuracy, ingress) | Sponsor estimate, not an FDA fee | typically $8,000–$25,000 |
| Clinical cohort validation pilot (about 20–40 subjects) | Sponsor estimate, not an FDA fee | typically $30,000–$120,000 |
| Commercial sensor provisioning | Sponsor estimate | typically $150–$600 per subject |
| Kitting, provisioning, reverse logistics | Sponsor estimate | typically $50–$150 per kit |
| Part 11 EDC gateway and cloud ingestion | Sponsor estimate | typically $10,000–$40,000 |
| Cybersecurity and privacy compliance audit | Sponsor estimate | typically $12,000–$30,000 |
Breakdown of Cost Categories
- Government Fees ($0 Base): There is no FDA user fee to include a DHT measurement tool in a medical device clinical trial. Initial IDE submissions to FDA CDRH do not incur MDUFA user fees. Fees apply only when submitting the final commercial marketing application (510(k), De Novo, PMA) for the primary device.
- Analytical and Clinical Validation: Conducting bench verification and clinical validation in a representative patient subgroup typically costs between $38,000 and $145,000, depending on whether reference gold standards (e.g., continuous telemetry or metabolic carts) are required.
- Subject Provisioning & Kitting: Purchasing commercial wearables or dedicated sensor hardware, pre-configuring software profiles, and managing shipping and returns represents a direct operational line item per enrolled patient.
- Data Infrastructure & Security: Building secure, 21 CFR Part 11 compliant data pipelines with immutable audit trails, encrypted cloud storage, and automated EDC integration is critical to protect study data integrity.
DHT Endpoint 30/60/90-Day Q-Sub, V&V, and SAP Plan for Device Investigations
Medical device clinical project teams deploying digital endpoints should execute the following 90-day integration plan:
| Window | Focus |
|---|---|
| Days 1–30 | Classify investigational article vs measurement tool; map MAH and COI; author a Q-Submission briefing package. |
| Days 31–60 | Execute analytical verification, a clinical validation pilot against a reference where one exists, and usability/battery checks. |
| Days 61–90 | Lock the DHT measure into the ICH E9(R1) estimand in the SAP; validate the Part 11 pipeline; finalize CIP / IDE / IRB packages. |
Phase 1: Days 1–30 — Regulatory Strategy & Pre-Submission Filing
- Determine Regulatory Role: Formally document whether the DHT is the investigational device under 21 CFR Part 812 or an endpoint measurement tool governed by the December 2023 guidance.
- Define MAH and COI: Apply the August 2026 discussion paper framework to define the Meaningful Aspect of Health and Concept of Interest before finalizing sensor selection.
- Submit Pre-Submission (Q-Sub): Submit a formal Q-Submission to CDRH requesting written feedback on the fit-for-purpose V&V plan and proposed digital endpoint definition.
Phase 2: Days 31–60 — Evidence Generation & Usability Testing
- Execute Sensor Verification: Compile bench testing data demonstrating sensor accuracy, resolution, measurement range, and environmental tolerance.
- Conduct Clinical Validation: Execute a pilot validation study in patients with the target clinical condition, correlating DHT measurements against established clinical reference standards.
- Usability & Adherence Evaluation: Conduct human factors testing evaluating device placement, charging frequency, app connectivity, and data synchronization.
Phase 3: Days 61–90 — Statistical Analysis Plan & Data Architecture
- Draft Estimand Section in SAP: Document the 5-attribute estimand structure under ICH E9(R1), defining exact statistical handling of missing data, non-wear time, and intercurrent clinical events.
- EDC / Part 11 Validation: Audit the cloud data ingestion infrastructure, ensuring end-to-end encryption, automated audit logging, and electronic signature compliance under 21 CFR Part 11.
- Finalize IDE Protocol: Incorporate the completed fit-for-purpose V&V dossier into the clinical investigational plan and submit to the lead Institutional Review Board (IRB) and FDA CDRH.
Frequently Asked Questions
If the wearable already has a 510(k), can we skip DHT verification and validation in this device trial?
No. A 510(k) clearance demonstrates that a wearable is substantially equivalent to a predicate for its cleared intended use (typically general wellness or OTC heart rate monitoring). It does not prove that the sensor is clinically accurate, sensitive to change, or fit-for-purpose for measuring a specific primary or secondary efficacy endpoint in your clinical trial cohort. The sponsor must still provide protocol-specific fit-for-purpose verification and validation.
Does the December 2023 guidance mean FDA will not look at 21 CFR 820.30 for any DHT used in a study?
No. FDA's enforcement discretion regarding 21 CFR § 820.30 (design controls) applies only when a device-DHT is used solely as a remote data collection tool in a clinical study and fit-for-purpose V&V is documented. Discretion does not apply if the DHT is the investigational article being evaluated for marketing authorization, if it delivers active clinical management alerts, or if it is intended for commercial marketing outside the trial.
Is the August 2026 digitally derived measures paper binding on CDRH device investigations?
No. The August 2026 document ("Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations"; FDA Voices content current as of August 20, 2026) is a discussion paper, not formal FDA guidance. It represents collaborative cross-center thinking intended to foster scientific dialogue. The authoritative guidance for remote data acquisition remains the December 2023 final guidance.
Does citing a qualified MDDT, such as the Apple AFib History Feature, finish our endpoint argument?
Only if used strictly within its qualified Context of Use (COU). Under Section 507 of the FD&C Act, FDA reviewers accept an MDDT's validity without re-reviewing underlying data only when the tool is deployed exactly in accordance with its qualified COU. If a sponsor uses an MDDT in a different patient population, disease stage, or clinical setting, protocol-specific validation is still required.
Should we follow FDA's "DHTs for Drug Development" program page for a PMA or 510(k) investigation?
No. The "DHTs for Drug Development" webpage is managed by CDER for pharmaceutical clinical trials under 21 CFR Part 312. While general scientific measurement principles are shared, medical device clinical investigations are governed by CDRH under 21 CFR Part 812, ISO 14155, and the December 2023 cross-center guidance.
Is there an FDA user fee to use a DHT as an endpoint measurement tool?
No. FDA does not charge user fees for incorporating digital measurement tools into clinical trial protocols. Standard MDUFA fees apply only when submitting premarket marketing applications (510(k), De Novo, PMA) for the primary medical device.
How Pure Global Supports Digital Health Clinical Evidence and Regulatory Strategy
Deploying digital health technologies, wearable sensors, and digitally derived measures in medical device clinical trials requires deep integration across clinical science, software validation, and FDA regulatory affairs.
Pure Global provides comprehensive clinical evidence advisory, regulatory strategy, and global market access support for innovative medical technology companies.
Our specialized digital health and clinical practices assist device sponsors with:
- Clinical Investigation Strategy & IDE Filings: Structuring IDE applications, Significant Risk (SR) determinations, and Clinical Investigational Plans under ISO 14155 and 21 CFR Part 812 through our Clinical Evaluations & Evidence practice.
- US FDA Pre-Submissions & Regulatory Access: Authoring Q-Submissions, negotiating digital endpoint validity with CDRH review branches, and managing premarket filings via our United States Market Access advisory practice.
- DHT Verification & Validation Dossiers: Drafting fit-for-purpose V&V protocols, usability testing frameworks, and sensor analytical validation reports.
- Statistical Estimand & SAP Integration: Structuring digital clinical outcome assessments into ICH E9(R1) compliant Statistical Analysis Plans.
To evaluate your digital health trial strategy, clinical evidence dossier, or global regulatory pathway, contact Pure Global.
Pure Global provides independent clinical evaluation, regulatory, and quality consulting. Pure Global is not the Food and Drug Administration (FDA), the European Medicines Agency (EMA), a European Notified Body, or an Institutional Review Board (IRB).
Sources
- Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (Final Guidance, December 2023) — U.S. Food and Drug Administration (Docket No. FDA-2021-D-1128; issued December 22, 2023).
- Digital Health Technologies for Remote Data Acquisition in Clinical Investigations; Guidance for Industry (FR Notice) — Office of the Federal Register / FDA (88 FR 88629, document 2023-28262).
- Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations (FDA Discussion Paper) — U.S. Food and Drug Administration (CBER/CDER/CDRH/OCE; August 2026 paper; FDA Voices content current as of August 20, 2026).
- FDA Weighs in on the Development and Use of Digitally Derived Measures in Clinical Investigations — FDA Voices (content current as of August 20, 2026).
- 21 CFR Part 812 — Investigational Device Exemptions — Electronic Code of Federal Regulations (FDA / CDRH).
- Medical Device Development Tools (MDDT) Program — U.S. Food and Drug Administration.
- ISO 14155:2020 Clinical investigation of medical devices for human subjects — Good clinical practice — International Organization for Standardization (ISO catalog 71690 is the 2020 edition; confirm any later edition on iso.org before citing a 2026 catalog number).
- ICH E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis — International Council for Harmonisation / FDA.
- FDA Medical Device User Fee Amendments (MDUFA) FY 2027 Schedule — U.S. Food and Drug Administration.